IP Library › Granted Patent US 12,605,396
Granted Patent B2
US 12,605,396 · App. 18/257,815 · Granted Apr 21, 2026

Methods of treating mastitis with an orthosomycin antimicrobial compound

Inventors: Ralf Warrass (Alzey, DE); Joachim Ullrich (Stadecken-Elsheim, DE)
Assignee: Intervet Inc.
A61K31/7048A61K9/0041A61K45/06A61P31/04
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,605,396
App. No.
18/257,815
Granted
Apr 21, 2026
Kind
B2
Abstract

This invention relates to methods of treatment and prevention of mastitis in animals by orthosomycin antimicrobial compounds.

Claims (15)

1 . A method for treating mastitis in an animal comprising administering to the animal an effective amount of an orthosomycin antimicrobial compound.

2 . The method according to claim 1 , wherein the orthosomycin antimicrobial compound is avilamycin.

3 . The method according to claim 1 , wherein the orthosomycin antimicrobial compound is evernimicin.

4 . The method according to claim 1 , wherein the orthosomycin antimicrobial compound is administered intramammarily.

5 . The method according to claim 1 , wherein the animal is a dry cow.

6 . The method according to claim 1 , wherein the animal is a lactating cow.

7 . The method according to claim 1 , wherein the mastitis is caused by Staphylococcus spp., Streptococcus spp, and/or Trueperella pyogenes.

8 . The method according to claim 1 wherein a therapeutically effective amount of the orthosomycin antimicrobial compound is administered to the mammary gland of a cow.

9 . The method according to claim 1 wherein the orthosomycin antimicrobial compound is administered to a cow with clinically manifest mastitis.

10 . The method according to claim 9 , wherein an additional non-antibiotic pharmacologically active component that is aimed at treatment of mastitis is administered to the animal in parallel.

11 . The method according to claim 10 , wherein an additional non-antibiotic pharmacologically active component is a specific or non-specific immunostimulant or a probiotic, a bacteriocin, a bacteriophage or a bacteriophage cocktail, phage endolysins or any other component that positively influences the body defense mechanism of the animal.

12 . An intramammary injector comprising a pharmaceutical composition comprising a therapeutically effective amount of an orthosomycin antimicrobial compound and a pharmaceutically acceptable carrier.

13 . The intramammary injector according to claim 12 comprising 25 to 1000 mg of the orthosomycin antimicrobial compound.

14 . The intramammary injector according to claim 12 , wherein the injector further comprises a teat seal formulation for forming a physical barrier in the teat canal of a dry cow.

15 . The intramammary injector according to claim 12 , wherein the orthosomycin antimicrobial compound is the sole antimicrobial compound.

Assignments (4)
CHANGE OF ADDRESS Recorded Sep 26, 2023
From: INTERVET INC.
To: INTERVET INC.
Reel/Frame 065028/0818 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 16, 2023
From: WARRASS, RAIF; ULLRICH, JOACHIM
To: MSD ANIMAL HEALTH INNOVATION GMBH
Reel/Frame 063970/0539 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 16, 2023
From: MSD ANIMAL HEALTH INNOVATION GMBH
To: INTERVET INTERNATIONAL B.V.
Reel/Frame 063970/0652 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 16, 2023
From: INTERVET INTERNATIONAL B.V.
To: INTERVET INC.
Reel/Frame 063970/0867 →
Priority Claims (1)
EP 20217194 · Dec 24, 2020 · regional
Continuity (1)
Related Publication 20240058366A1 · Feb 22, 2024
References Cited (21)
US 20150366797A1 · Page · 2015 [cited by examiner]
CN 1843331A · 2006 [cited by applicant]
JP 2010270016A · 2010 [cited by applicant]
JP 2011050373A · 2011 [cited by applicant]
WO 1998028011A1 · 1998 [cited by applicant]
WO 2014001353A1 · 2014 [cited by applicant]
WO 2014121343A1 · 2014 [cited by applicant]
WO 2015114163A2 · 2015 [cited by applicant]
WO 2017029271A1 · 2017 [cited by applicant]
WO 2018195237A1 · 2018 [cited by applicant]
WO WO2019243345A1 · 2019 [cited by examiner]
Kavault—avilamycin granule product sheet, Aug. 2015. (Year: 2015). [cited by examiner]
Heike Kaspar, Results of the antimicrobial agent susceptibility study raised in a representative, cross-sectional monitoring study on a national basis, International Journal of Medical Microbiology, 296(S2), 69-79, 2006. [cited by applicant]
Wallmann, J'Urgen et al., Results of an interlaboratory test on antimicrobial susceptibility testing of bacteria from animals by broth microdilution, International Journal of Antimicrobial Agents, 27, 482-490, 2006. [cited by applicant]
CAS No. 109545-84-8, 2 pages. [cited by applicant]
Chu, M. et al., Isolation and Characterization of Novel Oligosaccharides Related to Ziracin, J. Nat. Prod., 2002, pp. 1588-1593, 65. [cited by applicant]
Nickerson, S. et al., Antibiotic Therapy in Mastitis Control for Lactating and Dry Cows Introduction, University of Georgia Extension, 2019, 1-11, N/A. [cited by applicant]
Ollis, David W. et al., The orthosomycin family of antibiotics-I, Tetrahedron, 1979, 105-127, 35(1). [cited by applicant]
Pyorala, S., Treatment of mastitis during lactation, Irish Veterinary Journal, 2009, 40-44, 62. [cited by applicant]
Wagman, G.H. et al., Fermentation and Isolation of Everninomicin, Antimicrobial Agents and Chemotherapy, 1964, pp. 33-37. [cited by applicant]
Jones, R. N. et al., In vitro Gram-positive antimicrobial activity of evernimicin (SCH 27899), a novel oligosaccharide, compared with other antimicrobials: a multicentre international trial, Journal of Antimicrobial Che… [cited by applicant]